» Articles » PMID: 31354372

Impact of Smoking on Frequency and Spectrum of and Mutations in Treatment Naive Indonesian Lung Cancer Patients

Overview
Publisher Dove Medical Press
Date 2019 Jul 30
PMID 31354372
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Indonesia has the highest cigarette consumption in the world. We explored the clinical impact of smoking on the prevalence of and mutations and survival in this prospective study. 143 treatment naive lung cancer patients were recruited from Persahabatan Hospital, a national tertiary hospital. DNA from cytological specimens had been extracted and genotyped for both and mutations using a combination of PCR high resolution melting, restriction fragment length polymorphism (RFLP) and direct DNA sequencing. mutation frequency in never smokers (NS) and ever smokers (ES) were 75% and 56% ( = 0.0401), respectively. In this cohort, the overall mutation rate was 7%. Neither gender nor smoking history were associated with mutation significantly. However, transversion mutations were more common in male ES than transition mutations. Smoking history did not affect and mutation frequencies in women. Concurrent / mutation rate was 2.8% (4 of 143 patients). Four out of 91 mutation positive patients (4.4%) had simultaneous mutation. In region where cigarette consumption is prevalent, smoking history affected frequencies of and mutations, mainly in males.

Citing Articles

The role of oncogenes and tumor suppressor genes in determining survival rates of lung cancer patients in the population of North Sumatra, Indonesia.

Soeroso N, Ananda F, Sitanggang J, Vinolina N F1000Res. 2023; 11:853.

PMID: 37427014 PMC: 10329197. DOI: 10.12688/f1000research.113303.2.


Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers.

Cekani E, Epistolio S, Dazio G, Cefali M, Wannesson L, Frattini M Cancers (Basel). 2022; 14(17).

PMID: 36077640 PMC: 9454753. DOI: 10.3390/cancers14174103.


The Absence of Mutations in the Exon 2 KRAS Gene in Several Ethnic Groups in North Sumatra May Not the Main Factor for Lung Cancer.

Soeroso N, Ananda F, Pradana A, Tarigan S, Syahruddin E, Noor D Acta Inform Med. 2021; 29(2):108-112.

PMID: 34584333 PMC: 8443133. DOI: 10.5455/aim.2021.29.108-112.


Faculty Service-Learning Students as Home-Visitors: Outcomes of a Lifestyle Modification Program for Vulnerable Families With Residents in Rural Indonesian Communities.

Hang Kwok S, Pang P, Chung M, Wu C Front Public Health. 2021; 9:597851.

PMID: 34055707 PMC: 8149593. DOI: 10.3389/fpubh.2021.597851.

References
1.
Sasaki H, Okuda K, Kawano O, Endo K, Yukiue H, Yokoyama T . Nras and Kras mutation in Japanese lung cancer patients: Genotyping analysis using LightCycler. Oncol Rep. 2007; 18(3):623-8. View

2.
Riely G, Kris M, Rosenbaum D, Marks J, Li A, Chitale D . Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res. 2008; 14(18):5731-4. PMC: 2754127. DOI: 10.1158/1078-0432.CCR-08-0646. View

3.
Jackman D, Miller V, Cioffredi L, Yeap B, Janne P, Riely G . Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res. 2009; 15(16):5267-73. PMC: 3219530. DOI: 10.1158/1078-0432.CCR-09-0888. View

4.
Gazdar A . Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009; 28 Suppl 1:S24-31. PMC: 2849651. DOI: 10.1038/onc.2009.198. View

5.
Mao C, Qiu L, Liao R, Du F, Ding H, Yang W . KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer. 2009; 69(3):272-8. DOI: 10.1016/j.lungcan.2009.11.020. View